{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:42:16Z","timestamp":1791906136837,"version":"4.3.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"DOI":"10.1186\/s12886-026-04808-7","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T10:55:14Z","timestamp":1775904914000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Long-term disease control with anti-VEGF treat-and-extend treatment in macular edema due to retinal vein occlusion"],"prefix":"10.1186","volume":"26","author":[{"given":"Sarah","family":"Fischer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Hatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"issue":"8","key":"4808_CR1","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/S00347-015-0115-6","volume":"112","author":"N Feltgen","year":"2015","unstructured":"Feltgen N, Pielen A. [Retinal vein occlusion: Therapy of retinal vein occlusion]. Ophthalmologe. 2015;112(8):695\u2013706. https:\/\/doi.org\/10.1007\/S00347-015-0115-6. PubMed PMID: 26242852.","journal-title":"Ophthalmologe"},{"key":"4808_CR2","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S427416","author":"P Panos","year":"2023","unstructured":"Panos P GD, Lakshmanan A, Dadoukis P, Ripa M, Motta L, Amoaku WM. Faricimab: Transforming the Future of Macular Diseases Treatment-A Comprehensive Review of Clinical Studies. Drug Des Devel Ther. 2023. https:\/\/doi.org\/10.2147\/DDDT.S427416.","journal-title":"Drug Des Devel Ther"},{"key":"4808_CR3","doi-asserted-by":"publisher","unstructured":"Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(6). https:\/\/doi.org\/10.1016\/J.OPHTHA.2010.02.021.\u00a0PubMed PMID: 20398941.","DOI":"10.1016\/J.OPHTHA.2010.02.021"},{"key":"4808_CR4","doi-asserted-by":"publisher","unstructured":"Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(6). https:\/\/doi.org\/10.1016\/J.OPHTHA.2010.02.022 PubMed PMID: 20381871.","DOI":"10.1016\/J.OPHTHA.2010.02.022"},{"issue":"3","key":"4808_CR5","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.ophtha.2014.08.031","volume":"122","author":"PA Campochiaro","year":"2015","unstructured":"Campochiaro PA, Clark WL, Boyer DS, Heier JS, Brown DM, Vitti R, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology. 2015;122(3):538\u201344.031 PubMed PMID: 25315663.","journal-title":"Ophthalmology"},{"issue":"3","key":"4808_CR6","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/J.AJO","volume":"155","author":"DM Brown","year":"2013","unstructured":"Brown DM, Heier JS, Clark WL, Boyer DS, Vitti R, Berliner AJ, et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol. 2013;155(3):429\u2013e4377. https:\/\/doi.org\/10.1016\/J.AJO.2012.09.026 PubMed PMID: 23218699.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"4808_CR7","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ophtha.2013.08.012","volume":"121","author":"JF Korobelnik","year":"2014","unstructured":"Korobelnik JF, Holz FG, Roider J, Ogura Y, Simader C, Schmidt-Erfurth U, et al. Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study. Ophthalmology. 2014;121(1):202\u20138. PubMed PMID: 24084497.","journal-title":"Ophthalmology"},{"key":"4808_CR8","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez-Fern\u00e1ndez CA, Campo-Gesto A, L\u00f3pez-L\u00f3pez A, Gayoso-Rey M. Real-World Evidence for treat-and-extend regimen of ranibizumab therapy for macular oedema secondary to branch retinal vein occlusion. Pharmaceuticals (Basel). 2022;15(1). PubMed PMID: 35056116.","DOI":"10.3390\/ph15010059"},{"issue":"2","key":"4808_CR9","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/S40123-019-0184-8","volume":"8","author":"M Eleftheriadou","year":"2019","unstructured":"Eleftheriadou M, Nicholson L, D\u2019Alonzo G, Addison PKF. Real-Life Evidence for Using a Treat-and-Extend Injection Regime for Patients with Central Retinal Vein Occlusion. Ophthalmol Ther. 2019;8(2):289\u201396. https:\/\/doi.org\/10.1007\/S40123-019-0184-8. PubMed PMID: 30969404.","journal-title":"Ophthalmol Ther"},{"issue":"1","key":"4808_CR10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1159\/000487489","volume":"60","author":"MM Guichard","year":"2018","unstructured":"Guichard MM, Xavier AR, T\u00fcrksever C, Pruente C, Hatz K. Spectral-Domain Optical Coherence Tomography-Driven Treat-and-Extend and Pro Re Nata Regimen in Patients with Macular Oedema due to Retinal Vein Occlusion: 24-Month Evaluation and Outcome Predictors. Ophthalmic Res. 2018;60(1):29\u201337.https:\/\/doi.org\/10.1159\/000487489 PubMed PMID: 29566387.","journal-title":"Ophthalmic Res"},{"issue":"4","key":"4808_CR11","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/J.AJO.2007.02.024","volume":"143","author":"R Spaide","year":"2007","unstructured":"Spaide R. Ranibizumab according to need: a treatment for age-related macular degeneration. Am J Ophthalmol. 2007;143(4):679\u201380. https:\/\/doi.org\/10.1016\/J.AJO.2007.02.024. PubMed PMID: 17386275.","journal-title":"Am J Ophthalmol"},{"key":"4808_CR12","doi-asserted-by":"crossref","unstructured":"Hunter A, Williams M. Long-term outcomes for patients treated for macular oedema secondary to retinal vein occlusion: a systematic review. BMJ Open Ophthalmol. 2022;7(1).","DOI":"10.1136\/bmjophth-2022-001010"},{"issue":"6","key":"4808_CR13","doi-asserted-by":"publisher","first-page":"542","DOI":"10.3109\/08820538.2015.1009555","volume":"31","author":"J Bajric","year":"2016","unstructured":"Bajric J, Bakri SJ. Outcomes of Patients Initially Treated with Intravitreal Bevacizumab for Central Retinal Vein Occlusion: Long-Term Follow-Up. Semin Ophthalmol. 2016;31(6):542\u20137. https:\/\/doi.org\/10.3109\/08820538.2015.1009555. PubMed PMID: 25927243.","journal-title":"Semin Ophthalmol"},{"issue":"1","key":"4808_CR14","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ophtha.2013.08.038","volume":"121","author":"PA Campochiaro","year":"2014","unstructured":"Campochiaro PA, Sophie R, Pearlman J, Brown DM, Boyer DS, Heier JS, et al. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology. 2014;121(1):209\u201319. PubMed PMID: 24112944.","journal-title":"Ophthalmology"},{"issue":"3","key":"4808_CR15","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/IAE.0000000000001579","volume":"38","author":"I Chatziralli","year":"2018","unstructured":"Chatziralli I, Theodossiadis G, Chatzirallis A, Parikakis E, Mitropoulos P, Theodossiadis P, RANIBIZUMAB FOR RETINAL, VEIN OCCLUSION. Predictive Factors and Long-Term Outcomes in Real-Life Data. Retina. 2018;38(3):559\u201368. 10. 1097\/IAE.0000000000001579 PubMed PMID: 28248827.","journal-title":"Retina"},{"key":"4808_CR16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ajo.2019.03.029","volume":"205","author":"M Iftikhar","year":"2019","unstructured":"Iftikhar M, Mir TA, Hafiz G, Zimmer-Galler I, Scott AW, Solomon SD, et al. Loss of Peak Vision in Retinal Vein Occlusion Patients Treated for Macular Edema. Am J Ophthalmol. 2019;205:17\u201326. PubMed PMID: 30954469.","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"4808_CR17","doi-asserted-by":"publisher","first-page":"e1199","DOI":"10.1111\/aos.15068","volume":"100","author":"K Nanji","year":"2022","unstructured":"Nanji K, Khan M, Khalid MF, Xie JS, Sarohia GS, Phillips M, et al. Treat-and-extend regimens of anti-vascular endothelial growth factor therapy for retinal vein occlusions: a systematic review and meta-analysis. Acta Ophthalmol. 2022;100(6):e1199\u2013208. 10. 1111\/AOS.15068 PubMed PMID: 34845830.","journal-title":"Acta Ophthalmol"},{"key":"4808_CR18","doi-asserted-by":"crossref","unstructured":"Jaggi D, Nagamany T, Wolf S, Zinkernagel MS, Heussen FM. Aflibercept for central retinal vein occlusions: long-term outcomes of a \u2018Treat-and-Extend\u2019 regimen. BMJ Open Ophthalmol. 2024;9(1).","DOI":"10.1136\/bmjophth-2024-001659"},{"key":"4808_CR19","doi-asserted-by":"crossref","unstructured":"Chatziralli I, Theofilou P, Kazantzis D, Agapitou C, Karmiris E, Risi-Koziona A, et al. Intravitreal aflibercept for macular edema due to central retinal vein occlusion: 5-year results of a real-world study (INTRAMED-CRVO). Retina. 2025.","DOI":"10.1097\/IAE.0000000000004477"},{"issue":"3","key":"4808_CR20","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1159\/000514721","volume":"64","author":"H Giannakaki-Zimmermann","year":"2021","unstructured":"Giannakaki-Zimmermann H, Behrndt A, Hoffmann L, Guichard MM, T\u00fcrksever C, Pr\u00fcnte C, et al. Predictors for 2-Year Functional and Morphological Outcomes of a Treat-and-Extend Regimen with Ranibizumab in Patients with Diabetic Macular Edema. Ophthalmic Res. 2021;64(3):465\u201375. PubMed PMID: 33498045.","journal-title":"Ophthalmic Res"},{"issue":"4","key":"4808_CR21","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1159\/000485852","volume":"239","author":"K Hatz","year":"2018","unstructured":"Hatz K, Ebneter A, Tuerksever C, Pruente C, Zinkernagel M. Repeated Dexamethasone Intravitreal Implant for the Treatment of Diabetic Macular Oedema Unresponsive to Anti-VEGF Therapy: Outcome and Predictive SD-OCT Features. Ophthalmologica. 2018;239(4):205\u201314. PubMed PMID: 29402873.","journal-title":"Ophthalmologica"},{"issue":"7","key":"4808_CR22","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1097\/IAE.0B013E3181","volume":"30","author":"NZ Gregori","year":"2010","unstructured":"Gregori NZ, Feuer W, Rosenfeld PJ. Novel method for analyzing snellen visual acuity measurements. Retina. 2010;30(7):1046\u201350. https:\/\/doi.org\/10.1097\/IAE.0B013E3181. D87E04 PubMed PMID: 20559157.","journal-title":"Retina"},{"issue":"2","key":"4808_CR23","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1177\/1120672120904669","volume":"31","author":"HJ Hogg","year":"2021","unstructured":"Hogg HJ, Di Simplicio S, Pearce MS. Ranibizumab and aflibercept intravitreal injection for treatment na\u00efve and refractory macular oedema in branch retinal vein occlusion. Eur J Ophthalmol. 2021;31(2):548\u201355. PubMed PMID: 32009462.","journal-title":"Eur J Ophthalmol"},{"issue":"10","key":"4808_CR24","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1007\/s00417-021-05150-y","volume":"259","author":"DG Park","year":"2021","unstructured":"Park DG, Jeong WJ, Park JM, Kim JY, Ji YS, Sagong M. Prospective trial of treat-and-extend regimen with aflibercept for branch retinal vein occlusion: 1-year results of the PLATON trial. Graefes Arch Clin Exp Ophthalmol. 2021;259(10):2879\u201386. 05150-Y PubMed PMID: 33914158.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"4808_CR25","doi-asserted-by":"publisher","first-page":"605","DOI":"10.18240\/IJO","volume":"10","author":"B Mo","year":"2017","unstructured":"Mo B, Zhou HY, Jiao X, Zhang F. Evaluation of hyperreflective foci as a prognostic factor of visual outcome in retinal vein occlusion. Int J Ophthalmol. 2017;10(4):605\u201312. https:\/\/doi.org\/10.18240\/IJO. 2017.04.17 PubMed PMID: 28503435.","journal-title":"Int J Ophthalmol"},{"issue":"6","key":"4808_CR26","doi-asserted-by":"publisher","first-page":"3334","DOI":"10.1167\/IOVS.10-6097","volume":"52","author":"UEK Wolf-Schnurrbusch","year":"2011","unstructured":"Wolf-Schnurrbusch UEK, Ghanem R, Rothenbuehler SP, Enzmann V, Framme C, Wolf S. Predictors of short-term visual outcome after anti-VEGF therapy of macular edema due to central retinal vein occlusion. Invest Ophthalmol Vis Sci. 2011;52(6):3334\u20137. https:\/\/doi.org\/10.1167\/IOVS.10-6097. PubMed PMID: 21087958.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"4808_CR27","first-page":"890","volume":"15","author":"H Liu","year":"2018","unstructured":"Liu H, Li S, Zhang Z, Shen J. Predicting the visual acuity for retinal vein occlusion after ranibizumab therapy with an original ranking for macular microstructure. Exp Ther Med. 2018;15(1):890\u20136. PubMed PMID: 29399095.","journal-title":"Exp Ther Med"},{"issue":"1","key":"4808_CR28","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1001\/jamaophthalmol.2018.4484","volume":"137","author":"AS Babiuch","year":"2019","unstructured":"Babiuch AS, Han M, Conti FF, Wai K, Silva FQ, Singh RP. Association of Disorganization of Retinal Inner Layers With Visual Acuity Response to Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Secondary to Retinal Vein Occlusion. JAMA Ophthalmol. 2019;137(1):38\u201346. PubMed PMID: 30286219.","journal-title":"JAMA Ophthalmol"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-026-04808-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-04808-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-026-04808-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T12:02:34Z","timestamp":1779192154000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12886-026-04808-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4808"],"URL":"https:\/\/doi.org\/10.1186\/s12886-026-04808-7","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,11]]},"assertion":[{"value":"26 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants included in this analysis had provided general written consent. For individuals for whom obtaining consent was impractical or not feasible\u2014such as those no longer under treatment at our institution at the time of data analysis\u2014participation was based on presumed consent, in line with the approval of the local ethics committee (Ethics Committee of Northwestern Switzerland, EKNZ; approval number 2023\u2009\u2212\u200901246). Consequently, patients consented to the use of their health-related personal information for scientific purposes. The study was performed in compliance with the ethical principles outlined in the Declaration of Helsinki and adhered to the Good Clinical Practice (GCP) standards of the International Council for Harmonisation (ICH).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"KH: Advisory board\/consulting for Apellis, Astellas, Amgen, Bayer, Novartis, Roche, Allergan\/AbbVie; honoraria\/support for lectures or symposia from Apellis, Bayer, Biogen, Johnson & Johnson, Novartis, Roche, Sandoz, Th\u00e9a Pharma, Zeiss, Allergan\/AbbVie, Heidelberg Engineering; contract research\/research support from Bayer, Novartis, Roche, Allergan\/AbbVie, Janssen (Johnson & Johnson), ONL Therapeutics.No financial disclosures by all other authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"265"}}